Focused On-demand Library for Receptor-type tyrosine-protein phosphatase epsilon

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P23469

UPID:

PTPRE_HUMAN

Alternative names:

Alternative UPACC:

P23469; Q13345; Q5VWH3; Q5VWH4; Q96KQ6

Background:

Receptor-type tyrosine-protein phosphatase epsilon, encoded by the gene P23469, plays a pivotal role in various cellular processes. Isoform 1 is crucial for signaling transduction pathways and phosphoprotein network topology in red blood cells and may influence osteoclast formation. Isoform 2, on the other hand, acts as a negative regulator of insulin receptor signaling in skeletal muscle, affecting glucose uptake and phosphorylation events. Both isoforms negatively regulate FceRI-mediated signal transduction, impacting cytokine production and degranulation.

Therapeutic significance:

Understanding the role of Receptor-type tyrosine-protein phosphatase epsilon could open doors to potential therapeutic strategies. Its involvement in insulin signaling and immune response modulation presents a unique opportunity for the development of treatments targeting metabolic disorders and inflammatory conditions.